Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXRN Injection in Cancer Cachexia
NCT07231120Phase 1Recruiting
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of SXRN in cancer anorexia-cachexia syndrome (CACS), sponsored by Jiangsu Nutai Biologics Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 90 days, Dose Limiting Toxicities at 21 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
SXRN
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT07231120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231120.